

2026 6 Tier Standard - AmeriHealth Caritas VIP Care DE (HMO-DSNP)

2026 Step Therapy Criteria

CURRENT AS OF 03/01/2026

anticonvulsant step therapy

Products Affected

- FYCOMPA SUSPENSION 0.5 MG/ML ORAL
- *levetiracetam tablet disintegrating soluble 250 mg oral*
- *levetiracetam tablet disintegrating soluble 500 mg oral*
- *perampanel suspension 0.5 mg/ml oral*
- *perampanel tablet 10 mg oral*
- *perampanel tablet 12 mg oral*
- *perampanel tablet 2 mg oral*
- *perampanel tablet 4 mg oral*
- *perampanel tablet 6 mg oral*
- *perampanel tablet 8 mg oral*
- SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL
- SYMPAZAN FILM 10 MG ORAL
- SYMPAZAN FILM 20 MG ORAL
- SYMPAZAN FILM 5 MG ORAL
- XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL
- XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL
- XCOPRI TABLET 100 MG ORAL
- XCOPRI TABLET 150 MG ORAL
- XCOPRI TABLET 200 MG ORAL
- XCOPRI TABLET 25 MG ORAL
- XCOPRI TABLET 50 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X200 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X100 MG ORAL
- ZONISADE SUSPENSION 100 MG/5ML ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of two generic anticonvulsants. Step 2: Once two generic anticonvulsants have been tried, failed, or contraindicated patients can receive therapy with Spritam, generic levetiracetam oral disintegrating tablet, Sympazan, Xcopri, Fycompa, generic perampanel or Zonisade oral solution.
----------	--

antidepressant step therapy

Products Affected

- EXXUA TABLET EXTENDED RELEASE 24 HOUR 18.2 MG ORAL
- EXXUA TABLET EXTENDED RELEASE 24 HOUR 36.3 MG ORAL
- EXXUA TABLET EXTENDED RELEASE 24 HOUR 54.5 MG ORAL
- EXXUA TABLET EXTENDED RELEASE 24 HOUR 72.6 MG ORAL
- EXXUA TITRATION PACK TABLET EXTENDED RELEASE 24 HOUR 18.2 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of either (1) two generic antidepressants OR (2) Drizalma and one generic antidepressant. Step 2: Once two step one antidepressants have been tried, failed, or contraindicated patient can receive therapy with Fetzima or Exxua.
----------	--

brinzolamide and dorzolamide-timolol PF step therapy

Products Affected

- *brinzolamide suspension 1 % ophthalmic*
- *dorzolamide hcl-timolol mal pf solution 2-0.5 % ophthalmic*

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of formulary dorzolamide or dorzolamide/timolol ophthalmic solution. Step 2: Once dorzolamide or dorzolamide/timolol ophthalmic solution has been tried, failed, or contraindicated the patient can receive therapy with brinzolamide or Dorzolamide-Timolol PF Ophthalmic Solution.
----------	--

drizalma step therapy

Products Affected

- DRIZALMA SPRINKLE CAPSULE
DELAYED RELEASE SPRINKLE 20
MG ORAL
- DRIZALMA SPRINKLE CAPSULE
DELAYED RELEASE SPRINKLE 30
MG ORAL
- DRIZALMA SPRINKLE CAPSULE
DELAYED RELEASE SPRINKLE 40
MG ORAL
- DRIZALMA SPRINKLE CAPSULE
DELAYED RELEASE SPRINKLE 60
MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of generic formulary duloxetine. Step 2: Once generic formulary duloxetine has been tried, failed, or contraindicated the patient can receive therapy with drizalma.
----------	--

febuxostat step therapy

Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of allopurinol tablet. Step 2: Once allopurinol tablet has been tried, failed, or contraindicated patients can receive therapy with Febuxostat.
----------	---

netarsudil step therapy

Products Affected

- RHOPRESSA SOLUTION 0.02 %
OPHTHALMIC
- ROCKLATAN SOLUTION 0.02-0.005 %
OPHTHALMIC

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of latanoprost or travoprost. Step 2: Once latanoprost or travoprost has been tried, failed, or contraindicated patients can receive therapy with Rhopressa or Rocklatan.
----------	---

ongentys step therapy

Products Affected

- ONGENTYS CAPSULE 25 MG ORAL
- ONGENTYS CAPSULE 50 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of entacapone or carbidopa-levodopa-entacapone. Step 2: Once entacapone or carbidopa-levodopa-entacapone has been tried, failed, or contraindicated patients can receive therapy with Ongentys.
----------	---

savella step therapy

Products Affected

- SAVELLA TABLET 100 MG ORAL
- SAVELLA TABLET 12.5 MG ORAL
- SAVELLA TABLET 25 MG ORAL
- SAVELLA TABLET 50 MG ORAL
- SAVELLA TITRATION PACK 12.5 & 25 & 50 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication to duloxetine or pregabalin. Step 2: Once duloxetine or pregabalin has been tried, failed or contraindicated patients can receive therapy with Savella.
----------	---

topical immunomodulators step therapy

Products Affected

- *pimecrolimus cream 1 % external*
- *tacrolimus ointment 0.03 % external*
- *tacrolimus ointment 0.1 % external*

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of two topical corticosteroids. Step 2: Once two topical corticosteroids have been tried, failed, or contraindicated patients can receive therapy with generic pimecrolimus or generic topical tacrolimus.
----------	--

urinary incontinence agents step therapy

Products Affected

- *darifenacin hydrobromide er tablet extended release 24 hour 15 mg oral*
- *darifenacin hydrobromide er tablet extended release 24 hour 7.5 mg oral*
- *trospium chloride er capsule extended release 24 hour 60 mg oral*

Details

Criteria	Step 1: First line therapy should be a documented trial, failure or contraindication of 2 of the following: oxybutynin, oxybutynin ER, trospium, tolterodine, tolterodine ER, fesoterodine ER, or solifenacin. Step 2: Once two of the medications listed in Step 1 have been tried, failed, or contraindicated, patients can receive therapy with trospium ER or darifenacin ER
-----------------	---

xhance

Products Affected

- XHANCE EXHALER SUSPENSION 93
MCG/ACT NASAL

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of generic fluticasone or mometasone nasal spray. Step 2: Once generic fluticasone or mometasone nasal spray have been tried, failed, or contraindicated patients can receive therapy with Xhance.
----------	--

Index

B

brinzolamide suspension 1 % ophthalmic... 3

D

darifenacin hydrobromide er tablet extended
release 24 hour 15 mg oral..... 10

darifenacin hydrobromide er tablet extended
release 24 hour 7.5 mg oral..... 10

dorzolamide hcl-timolol mal pf solution 2-
0.5 % ophthalmic 3

DRIZALMA SPRINKLE CAPSULE

DELAYED RELEASE SPRINKLE 20
MG ORAL 4

DRIZALMA SPRINKLE CAPSULE

DELAYED RELEASE SPRINKLE 30
MG ORAL 4

DRIZALMA SPRINKLE CAPSULE

DELAYED RELEASE SPRINKLE 40
MG ORAL 4

DRIZALMA SPRINKLE CAPSULE

DELAYED RELEASE SPRINKLE 60
MG ORAL 4

E

EXXUA TABLET EXTENDED RELEASE
24 HOUR 18.2 MG ORAL..... 2

EXXUA TABLET EXTENDED RELEASE
24 HOUR 36.3 MG ORAL..... 2

EXXUA TABLET EXTENDED RELEASE
24 HOUR 54.5 MG ORAL..... 2

EXXUA TABLET EXTENDED RELEASE
24 HOUR 72.6 MG ORAL..... 2

EXXUA TITRATION PACK TABLET

EXTENDED RELEASE 24 HOUR 18.2
MG ORAL 2

F

febuxostat tablet 40 mg oral..... 5

febuxostat tablet 80 mg oral..... 5

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 120 MG ORAL ... 2

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 20 MG ORAL 2

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 40 MG ORAL 2

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 80 MG ORAL 2

FETZIMA TITRATION CAPSULE ER 24

HOUR THERAPY PACK 20 & 40 MG

ORAL..... 2

FYCOMPA SUSPENSION 0.5 MG/ML

ORAL..... 1

L

levetiracetam tablet disintegrating soluble

250 mg oral 1

levetiracetam tablet disintegrating soluble

500 mg oral 1

O

ONGENTYS CAPSULE 25 MG ORAL.... 7

ONGENTYS CAPSULE 50 MG ORAL.... 7

P

perampanel suspension 0.5 mg/ml oral..... 1

perampanel tablet 10 mg oral..... 1

perampanel tablet 12 mg oral..... 1

perampanel tablet 2 mg oral..... 1

perampanel tablet 4 mg oral..... 1

perampanel tablet 6 mg oral..... 1

perampanel tablet 8 mg oral..... 1

pimecrolimus cream 1 % external..... 9

R

RHOPRESSA SOLUTION 0.02 %

OPHTHALMIC 6

ROCKLATAN SOLUTION 0.02-0.005 %

OPHTHALMIC 6

S

SAVELLA TABLET 100 MG ORAL..... 8

SAVELLA TABLET 12.5 MG ORAL..... 8

SAVELLA TABLET 25 MG ORAL..... 8

SAVELLA TABLET 50 MG ORAL..... 8

SAVELLA TITRATION PACK 12.5 & 25

& 50 MG ORAL 8

SPRITAM TABLET DISINTEGRATING

SOLUBLE 250 MG ORAL 1

SPRITAM TABLET DISINTEGRATING

SOLUBLE 500 MG ORAL 1

SYMPAZAN FILM 10 MG ORAL..... 1

SYMPAZAN FILM 20 MG ORAL..... 1

SYMPAZAN FILM 5 MG ORAL..... 1

T

tacrolimus ointment 0.03 % external 9

tacrolimus ointment 0.1 % external 9

trospium chloride er capsule extended
release 24 hour 60 mg oral..... 10

X

XCOPRI (250 MG DAILY DOSE)
TABLET THERAPY PACK 100 & 150
MG ORAL 1
XCOPRI (350 MG DAILY DOSE)
TABLET THERAPY PACK 150 & 200
MG ORAL 1
XCOPRI TABLET 100 MG ORAL 1
XCOPRI TABLET 150 MG ORAL 1
XCOPRI TABLET 200 MG ORAL 1
XCOPRI TABLET 25 MG ORAL 1

XCOPRI TABLET 50 MG ORAL 1
XCOPRI TABLET THERAPY PACK 14 X
12.5 MG & 14 X 25 MG ORAL..... 1
XCOPRI TABLET THERAPY PACK 14 X
150 MG & 14 X200 MG ORAL..... 1
XCOPRI TABLET THERAPY PACK 14 X
50 MG & 14 X100 MG ORAL..... 1

XHANCE EXHALER SUSPENSION 93
MCG/ACT NASAL 11

Z

ZONISADE SUSPENSION 100 MG/5ML
ORAL..... 1